IL6 and COVID-19: Although there are significant differences in terms of age, co-morbidities, and blood parameters, multivariate analysis still showed that the expression of MPO, ADA, CCL22, TNFα, and IL-6 mRNA in nasopharyngeal specimens is higher in COVID-19 patients when compared with the control group.